Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic benefit of oritavancin administered as a single 1200 mg IV dose.
Critère d'inclusion
- wound infection,Abscess,Systemic Inflammation,Cellulitis